Hongming Pan

机构：Harbin Medical University, Chinese Academy of Sciences, Sir Run Run Shaw Hospital, Zhejiang Industry Polytechnic College, Third Affiliated Hospital of Harbin Medical University, Suzhou Thermal Engineering Research Institute, Institute of Software, University of Chinese Academy of Sciences, Huazhong University of Science and Technology, Zhejiang University · ORCID：0009-0007-8088-2961

发表论文 78 篇 · 总被引 1775 次 · h-index 23

代表论文

• Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial (2023 · The Lancet Oncology · 被引 438)
• Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial (2025 · Nature Medicine · 被引 34)
• Association of frailty with mortality in cancer survivors: results from NHANES 1999–2018 (2024 · Scientific Reports · 被引 27)
• Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study (2025 · Journal of Clinical Oncology · 被引 18)
• TRIM59 deficiency promotes M1 macrophage activation and inhibits colorectal cancer through the STAT1 signaling pathway (2024 · Scientific Reports · 被引 15)
• Efficacy and safety of dual blockade of HER2 and PD-1 in patients with HER2-positive gastric cancer: a retrospective, multicentre study (2024 · Scientific Reports · 被引 12)